ClinicalTrials.gg
Active, not recruitingNCT03324932Updated Oct 6, 2023

Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer

A Phase 3 interventional study of Denosumab Injection in Breast Cancer, sponsored by Kyoto Prefectural University of Medicine. Active, not recruiting at 1 site in Japan. Open to female participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Kyoto Prefectural University of Medicine · Phase 3, Interventional, and Prevention

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
20 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 24 studies testing denosumab in Breast Neoplasms — none open to participants now, 3 under way, 2 of them phase 3. Denosumab · Breast Neoplasms.

Planned enrollment
10th of 24
160 · median 53
Started
2017
with 2 others
Phase 3
9 of 24
none open now
Registered
18th of 24
by date
Lead sponsor
1 of 24
Kyoto Prefectural University of Medicine

Among the 24 studies testing denosumab in Breast Neoplasms, this one is the 10th largest by planned enrollment, is one of 3 that started in 2017, is one of 9 in phase 3, and was the 18th registered.

Breast Neoplasms

14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 24 studies testing denosumab in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing denosumab in Breast Neoplasms as a file.
02

Study summary

This multicenter, randomized, comparative study will evaluate the efficacy of denosumab to prevent the adjuvant therapy of aromatase inhibitors-induced loss of bone mineral density (BMD) in breast cancer patients with normal BMD. Investigators will compare the inhibitory effects of denosumab on bone loss between participants with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy for stage I-IIIA postmenopausal hormone-sensitive breast cancer and controls.

Read the detailed description

Normal BMD means T score is ≥-1.0 for the lumbar vertebrae (L1-L4) and/or the femoral neck.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • bone health
  • hormone-sensitive breast cancer
  • postmenopausal
  • aromatase inhibitor
  • bone mineral density
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients must meet all of the following items at the time of case registration:

  1. Patients with infiltrative breast cancer, aged ≥20 years, meeting the following definitions:

    • Those diagnosed with stage I, II, or IIIA breast cancer (Cancer Management Regulations, 11th version)
    • Those who underwent appropriate surgery, such as mastectomy and breast-preserving surgery
  2. Estrogen receptor (ER)- or progesterone receptor (PgR)-positive patients on immunohistochemical (IHC) staining
  3. Females meeting one of the following criteria for menopause:

    • Those, aged ≥55 years, without menstruation
    • Those, aged \<55 years, with amenorrhea for ≥12 months, or those diagnosed with menopause by attending physicians based on the FSH and estradiol levels
    • Those who underwent bilateral oophorectomy
  4. Patients in whom the BMD for the lumbar vertebrae (L1-L4) on DXA before the start of this study is ≥-1.0SD of the mean value of young adult females (YAM), and the BMD for the femoral neck is ≥-1.0SD of YAM
  5. Patients without lumbar vertebral or femoral fracture
  6. Those with an PS of 0-2
  7. Those with adequate organ functions (laboratory data within 4 weeks before case registration)

    • Leukocyte count, ≥3,000/mm3 or , ≥1,500/mm3
    • , ALT, ≤1.5-fold of the upper limit of the institutional reference range
    • Serum creatinine, ≤1.5-fold of the upper limit of the institutional reference range
  8. Case registration should be performed before the following point:Twelve weeks after the completion of surgery or postoperative chemotherapy (The completion of chemotherapy refers to the completion of the final course, involving the recovery phase.)
  9. Patients with an interval of ≥4 weeks after the discontinuation of therapy with bisphosphonates (oral preparations), estrogen preparations, raloxifene, calcitonin preparations, vitamin K preparations, active vitamin D preparations, or ipriflavone preparations, which influence bones
  10. Those from whom written regarding study participation was obtained

Exclusion criteria

Exclusion Criteria:

Whether each patient meets any of the following items must be checked on case registration:

  1. Patients in whom distant was confirmed clinically or using imaging procedures at the time of case registration
  2. Those with bilateral breast cancer
  3. Those for whom postoperative hormonal therapy was started before consenting to study participation
  4. Those who received endocrine therapy within 52 weeks before consenting to study participation
  5. Those to whom bisphosphonate preparations were intravenously administered within 52 weeks before consenting to study participation
  6. Those with the following diseases that may affect DXA

    • Severe scoliosis, immobility, hyperostosis or osteosclerosis of the lumbar vertebrae, calcification of the abdominal aorta, and vertebral disease
  7. Those with a history of malignant tumors other than breast cancer within 260 weeks before consenting to study participation
  8. Those with dental diseases, such as infectious diseases of the teeth or jaw and tooth trauma. Those for whom tooth or jaw surgery is scheduled within 6 weeks after consenting to study participation (tooth extraction, implantation)
  9. Others who are considered to be ineligible by the chief investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Other
    AI+denosumab VS only AI

    We compare AI intake+denosumab injection and AI intake only in patients with normal BMD to whom Letrozole or Arimidex will be administered as postoperative endocrine therapy, and we assess the efficacy of denosumab injection on bone loss by adjuvant endocrine therapy.

    Drug: Denosumab Injection

Interventions

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. percentage change in the bone mineral density (BMD) for the lumbar vertebrae (L1-L4) on dual-energy X-ray absorptiometry (DXA)

    The change is a value obtained by subtracting 1 from the BMD after 12 months/baseline BMD is expressed as a percentage

    Time frame: 12 months after the start of this study

Secondary outcomes

  1. percentage change in the BMD for the lumbar vertebrae (L1-L4) on DXA

    percentage change in the BMD for the femoral neck: After 2/3/4/5 years

    Time frame: after 2, 3, 4, and 5 years

  2. percentage change in the BMD for the femoral neck

    percentage change in the BMD for the femoral neck: After 12 months and 2/3/4/5 years

    Time frame: after 12 months and 2/3/4/5 years

  3. percentage change in the BMD for the radius (an ultrasonic bone densimeter is used)institutions in which ultrasonic bone densimeters are used)

    percentage change in the BMD for the radius (an ultrasonic bone densimeter is used): After 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only institutions in which ultrasonic bone densimeters are used)

    Time frame: after 2 and 4 weeks, every 4 weeks thereafter (for 2 years after registration)(only

  4. Changes in Ca and bone metabolism markers

    Changes in Ca (mg/dL corrected by albumin level) and bone metabolism markers such as TRAP5b, bone-specific alkaline phosphatase (BSAP), blood pentosidine) by blood sampling at every 6 months

    Time frame: after 24 weeks

  5. Appearance rate of morbid fracture in all participants

    Appearance rate of morbid fracture up to 3 years in all participants. Morbid fractures include all types of fractures.

    Time frame: up to 3 years

  6. Disease-free survival

    Disease-free survival at the end of the study

    Time frame: at least 5 year

  7. Overall survival

    Overall survival at the end of the study

    Time frame: at least 5 year

  8. Appearance of adverse events

    Appearance rate of adverse events (such as hypocalcemia and necrosis of the jaw)

    Time frame: at least 5 year

  9. Quality of life (QOL)

    Quality of life(QOL), Japanese version Euro-Qol (EQ-5D-5L) evaluated by questionnaire at every 6 months

    Time frame: after 24 weeks

07

Study locations

1 site
  • Hisako Ono
    Kyoto, 6028566, Japan
08

References and documents

Publications

  • Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results. Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27. PubMed 30054855 ↗
  • Sakaguchi K, Ono H, Nakatsukasa K, Ishikawa T, Hasegawa Y, Takahashi M, Niikura N, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Miura D, Yamada K, Yoshimura M, Shioya H, Konishi E, Isao Y, Imai K, Fujikawa K, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer. Medicine (Baltimore). 2019 Aug;98(32):e16770. doi: 10.1097/MD.0000000000016770. PubMed 31393399 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2023, 75 months after the start.

Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 75 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2017
First posted
Oct 30, 2017
StartActual
Sep 25, 2017
Primary completionEst.
Dec 2023
CompletionEst.
Dec 2027
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03324932
Lead sponsor
Kyoto Prefectural University of Medicine
Responsible party
Hisako Ono, MD, PhD (Principal Invetstigator, Kyoto Prefectural University of Medicine) — Principal investigator
First posted
Oct 30, 2017
Start date
Sep 25, 2017
Primary completion
Dec 2023 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 6, 2023

Study contacts

Hisako Ono, PhD
study director · Kyoto Prefectural University of Medicine
Tetsuya Taguchi, PhD
principal investigator · Kyoto Prefectural University of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion